This is a Provisional Conference Programme. To download a PDF click here.
For further information on this event please contact us.
Day One
Monday 5th September 2022
08.45 onwards
Registration
09.50-10.00
Welcome & Opening Remarks
Sarah Gilbert
(Pandemic Sciences Institute, University of Oxford, Oxford, UK)
SESSION 1:
OPENING PLENARY SESSION
Moderator: Sarah Gilbert
(Pandemic Sciences Institute, University of Oxford, Oxford, UK)
10.00-10.30
‘A global perspective on universal influenza vaccines: What do we want and how will we use it?’
Christopher Chadwick, Martin Friede and Ann Moen
(World Health Organization, Geneva, Switzerland)
10.30-11.00
‘Development of an ELISA-Based Potency Assay for Inactivated Influenza Vaccines Using Cross-Reactive Nanobodies’
Chung Y. Cheung1, Sitara Dubey1, Martina Hadrovic1, Christine R. Ball2, Walter Ramage2, Jacqueline U. McDonald1, Ruth Harvey1, Simon E. Hufton2 and Othmar G. Engelhardt1
( 1 Vaccines Division, Scientific Research & Innovation, Medicines and Healthcare products Regulatory Agency, South Mimms, Potters Bar, UK; 2 Biotherapeutics Division, Scientific Research & Innovation, Medicines and Healthcare products Regulatory Agency, South Mimms, Potters Bar, UK)
11.00-11.30
‘From a mathematical model of influenza evolution to a novel universal vaccine’
Sunetra Gupta
(Blue Water Vaccines, Cincinnati, Ohio, US)
11.30-12.00
Coffee Break
SESSION 2:
UNIVERSAL VACCINES
Moderator: Christopher Chadwick
(WHO, Geneva, Switzerland)
12.00-12.30
‘Bill & Melinda Gates Foundation strategy for development of universal influenza vaccines’
Ros Hollingsworth
(BMGF, Seattle, Washington, USA)
12.30-13.00
‘The development of a new approach to influenza vaccination, from concept to efficacy testing’
Sarah Gilbert
(Pandemic Sciences Institute, University of Oxford, Oxford, UK)
13.00-14.00
Lunch Break
SESSION 3:
GENERAL
Moderator: Anke L.W. Huckriede
(University Medical Center Groningen, Groningen, The Netherlands)
14.00-14.30
‘Combining T-cell and Antibody-based approaches to develop more effective influenza vaccines’
Jeffrey Almond
(University of Oxford, Oxford, UK)
14.30-15.00
‘Iteratively designed hemagglutinin based H5Nx antigens generate a broad neutralising immune response in mice’
Sneha Vishwanath
(University of Cambridge, Cambridge, UK)
15.00-15.30
Tea Break
SESSION 4:
STANDARDISATION/ASSAYS/CORRELATES OF PROTECTION
Moderator: To be confirmed
15.30-16.00
‘Standardisation of serology assays used in the evaluation of vaccines’
Othmar G. Engelhardt
(MHRA, South Mimms, Potters Bar, UK)
16.00-16.30
‘Correlates of protection for influenza vaccines’
Noemi Guerrini and Emanuele Montimoli
(VisMederi SRl, Siena, Italy)
Day Two
Tuesday 6th September 2022
SESSION 5:
GENERAL
Moderator: To be confirmed
09.00-09.30
‘The evolution of influenza-specific humoral immune responses and its implications for universal influenza vaccination’
Anke L.W. Huckriede
(University Medical Center Groningen, Groningen, The Netherlands)
09.30-10.00
‘Improving the assessment of vaccine efficacy in preclinical trials’
Jose Gonzales Rojas
(Wageningen University, Wageningen, The Netherlands)
10.00-10.30
‘Utilisation of the human challenge model for vaccine development’
Brandon Londt and Andrew Catchpole
(hVIVO, London, UK)
10.30-11.00
Coffee Break
SESSION 6:
GENERAL
Moderator: To be confirmed
11.00-11.30
‘Pandemic influenza vaccine response: The role of new technologies’
Christopher Chadwick
(WHO, Geneva, Switzerland)
11.30-12.00
‘Can the principles of a universal flu vaccine design be applied to coronavirus?’
Sunetra Gupta, Brian Price, Erin Henderson and Joe Hernandez
(Blue Water Vaccines, Cinncinati, Ohio, USA)
12.00-12.30
‘SEC meets TRPS: Automated isolation and high-precision analysis of extracellular vesicles and viruses’
Camille Roesch1, Anoop K. Pal2, Shayne Harrel3, Robert Vogel2 and Murray Broom2
( 1 Izon Science Europe Ltd, Lyon, France; 2 Izon Science Ltd, Medford, Massachusetts, USA; 3 Izon Science Ltd, Christchurch, New Zealand)
12.30-13.30
Lunch Break
SESSION 7:
VACCINES – I
Moderator: Othmar Engelhardt
(MHRA, South Mimms, Potters Bar, UK)
13.30-14.00
‘Evaluation of efficacy, immunogenicity, and cross-reactivity of FLU-v, a universal influenza peptide vaccine tested in a clinical phase IIb trial’
F. Oftung1, L.M. Næss1, D. B.-Bratlie1, I. Laake1, E. James2, G. Stoloff2 and O. Pleguezuelos2
(1 Infection Control and Environmental Health, Norwegian Institute of Public Health, (NIPH) Norway; 2 PepTcell Ltd (trading as SEEK), London, UK)
14.00-14.30
‘Novel TLR7 adjuvants for universal vaccines’
Akihisa Fukushima
(Sumitomo Pharma Ltd, Japan)
14.30-15.00
Tea Break
SESSION 8:
GENERAL
Moderator: To be confirmed
15.00-15.30
‘Human T cell immunology of influenza’
Teresa Lambe
(Univerity of Oxford, Oxford, UK)
15.30-16.00
‘Title to be confirmed’
Sunetra Gupta
(Blue Water Vaccines, Cincinnati, Ohio. USA)
Day Three
Wednesday 7th September 2022
SESSION 9:
VACCINES – II
Moderator: Othmar Engelhardt
(MHRA, South Mimms, Potters Bar, UK)
09.00-09.30
‘Results of a Phase 2 study with OXV836 suggest effectiveness in preventing influenza-like illness and confirm good safety profile’
D. Guyon-Gellin2, I. Leroux-Roels1, J. Tourneur2, G. Leroux-Roels1, F. Nicolas2, P. Willems2 and A. Le Vert2
(1 Ghent University, Ghent, Belgium; 2 Osivax, Lyon, France)
09.30-10.00
‘Harnessing the clec9a-targeting strategy to boost the immunogenicity of the universal flu antigen vaccine candidate M2e’
Ranmali Kavishna1, Mireille Lahoud2 and Sylvie Alonso1
(1 Department of Microbiology & Immunology, Yong Loo Lin School of Medicine; and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore; 2 Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia)
10.00-10.30
‘The pig influenza challenge model’
Barbara Dema Jimenez and Elma Tchilian
(University of Oxford/The Pirbright Institute, Pirbright, Surrey, UK)
10.30-11.00
Coffee Break
SESSION 10:
GENERAL
Moderator: Sarah Gilbert
(Pandemic Sciences Institute, University of Oxford, Oxford, UK)
11.00-11.30
‘The potential impacts of next generation influenza vaccines in Kenya: A modelling and cost-effectiveness study’
Naomi R. Waterlow1, Sreejith Radhakrishnan1, Jeanette Dawa2,3, Edwin van Leeuwen1,4, Philipp Lambach5, Joseph Bresee6, Marie Mazur7, Rosalind M. Eggo1 and Mark Jit1
( 1 Centre for Mathematical Modeling of Infectious Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom; 2 Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya; 3 Washington State University – Global Health Kenya, Nairobi, Kenya; 4 Statistics, Modelling and Economics Department, UK Health Security Agency, London, United Kingdom; 5 Immunization Vaccines and Biologicals Department, World Health Organization, Geneva, Switzerland; 6 The Task Force for Global Health, Decatur, GA, USA; 7 Ready2Respond, USA)
11.30-12.00
‘Nano-flow cytometry: A platform for comprehensive virus and extracellular vesicle analysis’
Dimitri Aubert
(NanoFCM, Medicity, Nottingham, UK)
12.00-12.30
Latebreaker talk to be confirmed
12.30-12.40
Closing Remarks and UIV 2022 Conference Close
Sarah Gilbert
(Pandemic Sciences Institute, University of Oxford, Oxford, UK)
12.40
Lunch & Departure
This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.